Patents by Inventor Alexander K. C. Wong

Alexander K. C. Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRG1 is a tumor suppressor that is mutated in prostate and other cancer types
    Patent number: 6465629
    Abstract: The present invention relates to the relation of the BRG1 gene (also called SNF2&agr;) to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the BRG1 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: October 15, 2002
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
  • TMPRSS2 is a tumor suppressor
    Patent number: 6444419
    Abstract: The present invention relates to the relation of the TMPRSS2 gene to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the TMPRSS2 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: September 3, 2002
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
  • Human CDC14A gene
    Patent number: 6331614
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to human CDC14A gene which has been found to be mutated in certain tumor cell lines. More specifically, the invention relates to a novel sequence for the human CDC14A gene. The present invention further relates to somatic mutations in the CDC14A gene in human cancer and their use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the CDC14A gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the CDC14A gene for mutations, which are useful for diagnosing the predisposition to cancer.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: December 18, 2001
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, David H. -F. Teng, Sean V. Tavtigian
  • Carboxy-terminal BRCA1 interacting protein
    Patent number: 6235263
    Abstract: Recent evidence indicates that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid assay and an in vitro biochemical assay, it is here shown that a protein, B112, interacts specifically with the carboxy-terminal segment of human BRCA1 from residue 1602 to 1863. A germ line truncation mutation, 1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1 abolishes not only the transcription activation function, but also binding to B112. The B112 protein is apparently the same as an uncharacterized protein known as CtIP, the sequence of which was previously deposited in GenBank. Screenings of a panel of 92 tumor cell lines for mutations in the B112/CtIP sequence have identified a number of missense variants, including a non-conserved lysine to glutamic acid change at codon 337 in the pancreatic cancer line, BxPC3.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: May 22, 2001
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Paul L. Bartel, David H.-F. Teng, Sean V. Tavtigian
  • TMPRSS2 is a tumor suppressor
    Patent number: 6166194
    Abstract: The present invention relates to the relation of the TMPRSS2 gene to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the TMPRSS2 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: December 26, 2000
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
  • Carboxy-terminal BRCA1 interacting protein
    Patent number: 6030832
    Abstract: Recent evidence indicates that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid assay and an in vitro biochemical assay, it is here shown that a protein, B112, interacts specifically with the carboxy-terminal segment of human BRCA1 from residue 1602 to 1863. A germ line truncation mutation, 1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1 abolishes not only the transcription activation function, but also binding to B112. The B112 protein is apparently the same as an uncharacterized protein known as CtIP, the sequence of which was previously deposited in GenBank. Screenings of a panel of 92 tumor cell lines for mutations in the B112/CtIP sequence have identified a number of missense variants, including a non-conserved lysine to glutamic acid change at codon 337 in the pancreatic cancer line, BxPC3.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: February 29, 2000
    Assignee: Myriad Genetics, Inc.
    Inventors: Alexander K. C. Wong, Paul L. Bartel, David H. -F. Teng, Sean V. Tavtigian